11 companies are listed as custom peptide synthesis companies in China. 10 hold active US Drug Master Files for peptide APIs, most often for Tirzepatide, Semaglutide, Degarelix. 2 have a regulator record of GMP manufacturing. 2 score High (90 or more). 1 listing carries an open FDA warning letter, which caps the score at 60.
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Shenzhen peptide CDMO and API maker founded in 2009, with 13 cGMP lines and 85,000 L of SPPS/LPPS reactor volume. Holds US DMFs for 6 peptide APIs.
Suzhou peptide API and formulation maker founded in 2000, flagship of Tianma Pharma Group, offering CRO/CMO/CDMO services. Holds US DMFs for 8 peptide APIs.
Shanghai maker of protected amino acids, custom and catalogue peptides, drug peptides, cosmetic peptides and antibodies, with eight production bases.
Hangzhou peptide maker founded in 2014 offering pharmaceutical, cosmetic and catalog peptides plus peptide CRO/CDMO work; holds an active US DMF for semaglutide.
Hangzhou peptide developer offering peptide APIs, intermediates, impurities and ADC/PDC linkers plus custom synthesis and process development; holds an active US DMF for tirzepatide.
Ningxia API and peptide maker founded in 2016 in Pingluo, offering peptide API development and manufacturing; holds US DMFs for semaglutide and tirzepatide.
Weihai Sino-US joint venture founded 2016 making peptide APIs and cosmetic peptides; US DMFs for leuprolide and semaglutide.
Shenzhen peptide company founded in 2020 making GLP-1 peptide APIs, sterile vials and peptide reference materials at a Zhongshan plant; holds an active US DMF for tirzepatide.
Leshan-based peptide producer founded in 2015 with SPPS and LPPS lines; holds US DMFs for eptifibatide, semaglutide and tirzepatide.
Suzhou peptide CRDMO with GMP workshops built to ICH Q7; US DMFs for semaglutide and tirzepatide.
Harbin peptide API maker founded in 2011. Holds US DMFs for 11 peptide APIs. FDA issued it a CGMP warning letter in May 2026 that remains open.
11 companies. Each listing shows location, business model, documentation and a score from 0 to 100.
By score: Shenzhen JYMed Technology Co., Ltd. (JYMed Peptide) (90), Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. (90), GL Biochem (Shanghai) Ltd (75), Hangzhou Go Top Peptide Biotech Co., Ltd. (75), Hangzhou Hotide Biotech Co., Ltd. (75). Scores measure checkable evidence, not product quality, and paid placement does not change them.
Shenzhen JYMed Technology Co., Ltd. (JYMed Peptide), Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd., Hangzhou Go Top Peptide Biotech Co., Ltd., Hangzhou Hotide Biotech Co., Ltd., Ningxia LabsChem Co., Ltd., ReaLi Tide Biological Technology (Weihai) Co., Ltd, Shenzhen Alvantis Pharma Co., Ltd., Sichuan Jisheng Biopharmaceutical Co., Ltd, Suzhou Motif Biotech Co., Ltd and Harbin Jixianglong Biotech Co., Ltd. hold active Type II DMFs for peptide APIs in FDA's DMF list. A DMF is a confidential file submitted to FDA; FDA does not approve DMFs, but drug applications can reference them.
Confirm the legal entity, ask for lot-specific certificates of analysis that the testing lab can verify, check FDA warning letters and import alerts, and for GMP material ask for regulator inspection records rather than marketing claims.